FDA to allow emergency use of Gilead’s Covid-19 drug
The Food and Drug Administration announced Friday that it would permit emergency use of remdesivir, the antiviral medicine from Gilead Sciences, to treat patients with Covid-19.
The decision to issue an “emergency use authorization” was based on positive results from a government-conducted clinical trial, announced Wednesday, that showed remdesivir accelerated the recovery time of patients with Covid-19 compared to a placebo. At the same time, the government’s top infectious disease expert cautioned that the drug was not a “knockout.”
Read Original Article: FDA to allow emergency use of Gilead’s Covid-19 drug »
